

EXPERIENCES CHALLENGE

PRRS CONTROL

Terms and Conditions

1. Introduction.

- 1.1. Porcine Reproductive and Respiratory Syndrome (PRRS) remains one of the most significant health challenges for swine producers worldwide. Despite advances in biosecurity and management practices, the virus continues to cause major economic losses due to reproductive failure in sows and respiratory disease in growing pigs. As a result, vaccination strategies have become a cornerstone in PRRS control programs.

Among the available vaccines, modified live vaccines (MLV) are widely used due to their ability to induce both humoral and cellular immune responses, which are critical for protection against PRRS virus. However, MLV vaccines are not without limitations, as they may vary in efficacy against heterologous strains and carry some potential safety concerns. Despite these challenges, MLV vaccination remains the most practical and effective option to reduce clinical signs, improve herd immunity, and limit virus circulation in both breeding herds and growing pig populations.

This is why, in many countries, MLV vaccination is considered an essential tool for PRRS control, particularly when combined with strict biosecurity and herd management practices

- 1.2. UNISTRRAIN® PRRS (IM and ID), is a PRRS MLV vaccine- developed and manufactured by LABORATORIOS HIPRA, S.A. ("HIPRA"). UNISTRRAIN® PRRS (IM and ID) is marketed across numerous territories, either directly by HIPRA or through its affiliated companies and authorized distributors.

2. Object.

- 2.1. The objective of this scientific Challenge is to showcase the performance of UNISTRRAIN® PRRS on pigs under field conditions- either administered intramuscularly or intradermally-, by means of field data (hereinafter the "Data Trial").
- 2.2. The top 4 Data Trials will be selected for submission as abstracts at the 2027 AASV Annual Meeting, which is expected to take place from February 27th to March 2nd, 2027 in the city of Orlando (Florida), USA (see <https://www.aasv.org>). The author/s of each selected trial will be rewarded with the opportunity to attend the aforesaid event as presenter (either through a poster or an oral presentation).

3. Participation

- 3.1. The opening of this scientific Challenge will be announced at HIPRA's LinkedIn profile and/or <https://hipra.com/en/animal-health/knowledge/experiences-challenge-prrs-control>
- 3.2. The Challenge is open to veterinary professionals, particularly—but not exclusively—those specialized in the porcine species.
- 3.3. Any questions in connection with the Challenge shall be addressed to global.swine@hipra.com indicating as subject EXPERIENCES CHALLENGE PRRS CONTROL. The Jury members, their relatives, or HIPRA's employees cannot participate in the Challenge.
- 3.4. The Participation in this Challenge implies acceptance of strict confidentiality obligations by the Authors, who shall not be able to disclose the corresponding results to any third parties (and therefore will not be able to publish them) without the prior written approval by HIPRA. Participation in this Challenge also implies acceptance of the Terms and Conditions established in this document.
- 3.5. In order to participate in this scientific Challenge, the participants should submit the Data Trial as defined in point 4 below to the following e-mail address global.swine@hipra.com. Data Trial can be submitted until 23:59 on the **15th July 2026**.
- 3.6. The Jury's decision will be communicated to all participants on or before 1st September 2026 by means of publication at <https://www.hipra.com/>.
- 3.7. Failure to meet the Terms and Conditions of this scientific Challenge or failure to complete the mandatory information will result in the impossibility of participating in the Challenge.

4. Data Trial

- 4.1. Each Data Trial submitted during this scientific Challenge should have one main author (the “Author”) and must describe the Author’s own and original experience.
- 4.2. The Data Trial must be fully designed and conducted by the Author; who may nevertheless make use of the following resources provided by HIPRA: a) technical assistance by the local HIPRA team; b) HIPRA Diagnos- laboratory testing coupled with consulting and c) HIPRA Stats- data analysis service.
- 4.3. Any and all costs of conducting the trials- including the price for the required doses of UNISTRAIN PRRS- will be covered by the Author.
- 4.4. The Author declares to be the author of the Data Trial and to be entitled to assign its exploitation rights.
- 4.5. The Author declares that the trials have been conducted considering the ethical postulates and guidelines on animal protection.
- 4.6. The submitted Data Trials should include the following information:
 - 4.6.1. Description of the objective/s of the trial: 1) comparison of the live attenuated PRRS vaccine UNISTRAIN® PRRS (IM and ID) with other PRRS vaccines available on the market or with non-vaccination strategies 2) Evaluation of the performance and field efficacy of UNISTRAIN® PRRS (IM and ID) under field conditions.
 - 4.6.2. Description of the materials and methods (Number of pigs involved, vaccination programme applied, sampling schedule, and laboratory analyses performed).
 - 4.6.3. Description of the results including:
 - 4.6.3.1. Productive parameters
Mortality, average daily gain (ADG), feed conversion ratio (FCR), use of antibiotics, and any other relevant performance data obtained.
 - 4.6.3.2. Laboratory results
Viral load (PCR), serology results (ELISA), sequencing if applicable, and any other laboratory parameters assessed during the trial.

5. Evaluation

- 5.1. It will be based on four criteria: Scientific and technical quality, Originality and novelty, Clarity and Structure, and Significance and Impact, each worth 25 points, for a total of 100 points.

6. Jury

- 6.1. The Jury will be made up of the following professionals: Global Technical Manager (Swine Business Unit, HIPRA) Regional Technical Manager (HIPRA) and 2 externals PRRS experts.
- 6.2. The members of the Jury will elect the President from amongst themselves who, in the unlikely event of a tie, will have a deciding vote.
- 6.3. There is no right of appeal against the decision of the Jury.

7. Acknowledgements

- 7.1. The main reward of this scientific Challenge is acknowledgement of the top 4 positive experiences in PRRS CONTROL achieved through vaccination with UNISTRAIN® PRRS.
- 7.2. In order to not only acknowledge the Authors of 4 top Data Trial but also assist in their professional development, they will also be awarded with the attendance as presenters / authors (either through a poster or an oral presentation) at the at the 2027 AASV Annual Meeting, which is expected to take place from February 27th to March 2nd, 2027 in the city of Orlando (Florida), USA or any other meeting/congress of HIPRA’s choice should they were issues with the Author’s participation at the aforesaid event. All reasonable travel expenses, including 2027 AASV registration, will be covered by HIPRA.
- 7.3. In consideration of the aforesaid, the Authors of the top 4 Data Trials grant to HIPRA exploitations rights to the Data Trials and the associated image rights as indicated in the point 7.1 hereinbelow.
- 7.4. The award cannot be divided, nor be transferred to a different participant.

- 7.5. In the event that the selected Author cannot be contacted, the Jury will select the next one, and so on.
- 7.6. The value of the compensation is subject to applicable tax regulations.

8. Intellectual Property and Confidentiality

- 8.1. In consideration of the Acknowledgements as agreed in point 7 hereinabove, the Authors of the top 4 Data Trials assign exclusively to HIPRA any and all exploitation rights to Data Trials that they may hold and their respective copyrights. Likewise, the Authors authorize HIPRA to use their images and name in any and all photographs, images, videos, and performances or sound recordings which are taken from them in connection with the Challenge, always in relation to HIPRA's area of business. The images shall not be used contrary to the Authors' right to honour, reputation or good taste. HIPRA shall be able to edit, modify, publish, broadcast or combine the images with other images, text, graphics, film, audio, audio-visual works at any time and by means of any media. These assignments and authorizations have neither geographic nor time limits.

9. Processing of personal data

- 9.1. The personal data provided by the participants will be handled strictly in accordance with the regulations in force regarding personal data protection.
- 9.2. The data collected from the participants can be stored in a file owned by HIPRA and may be used to keep participants informed on the latest HIPRA's products and services in the field of veterinary medicine and animal health.
- 9.3. HIPRA's privacy policy is available at <https://www.hipra.com/en/privacy-policy>

10. Final provisions

- 10.1. HIPRA reserves the right to modify, for justified reasons, these Terms and Conditions, as well as the composition of the Jury.
- 10.2. All information concerning this scientific Challenge can be accessed at <https://hipra.com/en/animal-health/knowledge/experiences-challenge-prrs-control>
- 10.3. Any questions in connection with the Challenge shall be addressed to global.swine@hipra.com.

October 31st, 2025